Mosaic ImmunoEngineering (OTCMKTS:CPMV) Stock Price Up 697.3% – Time to Buy?

Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) shares traded up 697.3% on Monday . The stock traded as high as $0.6735 and last traded at $0.4784. 3,728 shares traded hands during mid-day trading, an increase of 470% from the average session volume of 654 shares. The stock had previously closed at $0.06.

Mosaic ImmunoEngineering Stock Performance

The firm has a market cap of $3.46 million, a price-to-earnings ratio of -5.32 and a beta of -0.82. The business’s 50-day moving average is $0.61 and its 200-day moving average is $0.61.

Mosaic ImmunoEngineering (OTCMKTS:CPMV) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.02) earnings per share (EPS) for the quarter.

Mosaic ImmunoEngineering Company Profile

Mosaic ImmunoEngineering (OTCMKTS:CPMV) is a development-stage biotechnology company focused on advancing immunotherapies and vaccine candidates through its proprietary nanoparticle platform. The company leverages virus-like particles derived from the cowpea mosaic virus (CPMV) to serve as both antigen carriers and immune stimulators, aiming to enhance the magnitude and durability of immune responses. By engineering these plant-based VLPs to display target antigens or adjuvant properties, Mosaic ImmunoEngineering seeks to create differentiated candidates for oncology indications and infectious disease prevention.

Operating out of the United States, Mosaic ImmunoEngineering is currently in preclinical stages of development.